Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
Quick Stats
Apr 02, 202648.3
AI Score
HOLD2.01
Volume Ratio
May 21, 2026
Next Earnings
13
+ve Days (30d)
17
-ve Days (30d)
ZBIO Stock Summary
Last updated Apr 02, 2026
ZBIO is currently trading at $21.46, positioned below its 200-day moving average of $23.22, suggesting bearish momentum. The stock has a 52-week range of $6.11 to $44.6.
Technical Analysis: The 50-day moving average stands at $23.03, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 44.753, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is 0.21, which is positive, indicating accumulation by institutional investors. Our AI-powered investment score rates ZBIO at 48.3/100 with a HOLD recommendation.
ZBIO (Zenas BioPharma, Inc. Common Stock) Indicators
Last updated Apr 02, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 44.753 |
| CMF (20) | 0.21 |
| ROC (10) | -8.173 |
| ADX (14) | 21.702 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | -1.249 |
| AROONOSC (14) | -71.429 |
| WILLAMS %R (14) | -38.081 |
| MFI (14) | 40.673 |
ZBIO Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
ZBIO Price vs Max Options Open Interest
ZBIO Max Change In Options Open Interest
ZBIO Options - Sort by Max open Interest (near term)
2nd April 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
ZBIO Daily Out of Money Options - Sort by Max open Interest (near term)
2nd April 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
ZBIO Daily In the Money Options - Sort by Max open Interest (near term)
2nd April 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
ZBIO Most Active Options by Volume(near term)
2nd April 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
Zenas BioPharma, Inc. Common Stock is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
ZBIO Moving Averages Analysis
ZBIO (Zenas BioPharma, Inc. Common Stock) Simple Moving Averages
Moving Averages are last updated Apr 02, 2026
| Days | MA |
|---|---|
| 10 | 20.61 |
| 20 | 22.52 |
| 30 | 23.64 |
| 50 | 23.03 |
| 100 | 27.97 |
| 200 | 23.22 |
ZBIO Fundamental Analysis
| P/E (Forward) | 0 |
| P/E (Trailing) | -- |
| Market Cap ($) | 1.2 billion |
| Earnings/Share ($) | -8.44 |
| Net Proft Margin (%) | 0 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -5.115 |
| EPS Estimate Next Year ($) | -4.885 |
| WallStreet Target Price ($) | 42 |
| Most Recent Quarter |